Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News NanoViricides Inc NNVC

Healthcare Biotechnology
NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:NNVC)

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Accesswire 8 days ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

Accesswire November 4, 2024

NanoViricides President Dr. Diwan to Present at the PODD Conference

Accesswire October 22, 2024

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

Accesswire October 15, 2024

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Accesswire October 8, 2024

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

Accesswire September 30, 2024

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including "Trojan Horse" Drugs

Accesswire September 26, 2024

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

Accesswire August 26, 2024

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -
A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

Accesswire August 19, 2024
View More News ››

Opinion & Analysis (NYSEAM:NNVC)

Micro cap biotech is nano-fighting the swine flu

AllPennyStocks.com April 29, 2009
View More Opinion ››

Bullboard Posts (NYSEAM:NNVC)

Exciting company, but posting almost same news

Just wondering why they keep posting repeatedly same news.  Management, just tell us the timeline of what you plan to do and that...
Adwari - August 20, 2024

NanoViricides, Inc. (NNVC): A Promising Biotech Tackling Vir

http://beyondspx.com/2024/08/02/nanoviricides-inc-nnvc-a-promising-biotech-tackling-viral-infections-with-innovative-nanomedicine...
MikeTester - August 3, 2024

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses

Just In: $NNVC A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1...
whytestocks - June 24, 2024

Orally Administered NV-387 Results in Ideal Flat Blood Conce

JUST IN: $NNVC Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral EffectA First-In...
whytestocks - June 11, 2024

Like a rocket

Hard to believe no one seems to be following this stock which is exploding!
lumbricus - May 8, 2024

monkeypox play

.
thedave2006 - August 5, 2022
View more Bullboard ››

Coelacanth Energy Inc.

Coelacanth Energy Inc.

Coelacanth Energy Inc. is a Montney-focused oil and natural gas exploration and development company, with lands located in ...
View More »